Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields

World Journal of Surgical Oncology

Josef Vymazal¹  František Tovaryš³  Martin Syrůček²  Vladimír Dbalý³  Jan Šroubek³  Jan Klener³  Jiří Keller⁵  Aaron Michael Rulseh⁴ 

[1] Department of Neurology, Charles University in Prague, 1st Medical Faculty, Prague, Czech Republic;Department of Pathology, Na Homolce Hospital, Prague, Czech Republic;Department of Neurosurgery, Na Homolce Hospital, Prague, Czech Republic;Department of Radiology, Na Homolce Hospital, Prague, Czech Republic;Charles University in Prague, 3rd Medical Faculty, Prague, Czech Republic

关键词: Long-term survival;    Tumor-treating fields;    Recurrent glioblastoma multiforme;    Glioblastoma multiforme;   

Others  :  827093
DOI  :  10.1186/1477-7819-10-220

 received in 2012-02-22, accepted in 2012-09-13,  发布年份 2012

【 摘 要 】

Glioblastoma multiforme (GBM) is the most common and malignant primary intracranial tumor, and has a median survival of only 10 to 14 months with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median survival to only five to seven months with optimal therapy. Tumor-treating fields (TTField) therapy is a novel treatment technique that has recently received CE and FDA approval for the treatment of RGBM, and is based on the principle that low intensity, intermediate frequency electric fields (100 to 300 kHz) may induce apoptosis in specific cell types. Our center was the first to apply TTField treatment to histologically proven GBM in a small pilot study of 20 individuals in 2004 and 2005, and four of those original 20 patients are still alive today. We report two cases of GBM and two cases of RGBM treated by TTField therapy, all in good health and no longer receiving any treatment more than seven years after initiating TTField therapy, with no clinical or radiological evidence of recurrence.

【 授权许可】

   
2012 Rulseh et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 7.

【 参考文献 】

• [1]Dobes M, Khurana VG, Shadbolt B, Jain S, Smith SF, Smee R, Dexter M, Cook R: Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000–2008): findings of a multicenter Australian study. Surg Neurol Int 2011, 2:176.
• [2]Dubrow R, Darefsky AS: Demographic variation in incidence of adult glioma by subtype, United States, 1992–2007. BMC Cancer 2011, 11:325. BioMed Central Full Text
• [3]Johnson DR, O’Neill BP: Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2012, 107:359-364.
• [4]Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G: Long-term survival with glioblastoma multiforme. Brain 2007, 130:2596-2606.
• [5]Deb P, Sharma MC, Mahapatra AK, Agarwal D, Sarkar C: Glioblastoma multiforme with long term survival. Neurol India 2005, 53:329-332.
• [6]Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009, 27:5743-5750.
• [7]Henriksson R, Asklund T, Poulsen HS: Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol 2011, 104:639-646.
• [8]Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y: Disruption of cancer cell replication by alternating electric fields. Cancer Res 2004, 64:3288-3295.
• [9]Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y: Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 2007, 104:10152-10157.
• [10]Pless M, Weinberg U: Tumor treating fields: concept, evidence and future. Expert Opin Investig Drugs 2011, 20:1099-1106.
• [11]Wong ET, Ram Z, Gutin PH, Stupp R: Updated survival data of the Phase III clinical trial of Novottf-100a versus best standard chemotherapy for recurrent glioblastoma. Neuro-Oncol 2011, 13:iii85-iii91.
• [12]Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.